^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Solid Tumor
    Drug:EGFR806-specific CAR T-cell therapy (EGFR-targeted CAR-T immunotherapy)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

    Excerpt:
    ...- Histologically diagnosed malignant, non-CNS solid tumor expressing EGFR...
    Trial ID:
    STRIvE-01
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

    Excerpt:
    ...CAR T cell distribution: The number of subjects with CAR T cell persistence in the cerebrospinal fluid (CSF) and peripheral blood as measured by flow cytometry`Expression of target epitope: assessment of whether EGFR expression changes in relapsed CNS tumors that were EGFR positive prior to treatment with CAR T cells via immunohistochemistry on resected tissue samples.`...
    Trial ID:
    NCT03638167
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    STRIvE-01: Phase I study of EGFR806 CAR T-cell immunotherapy for recurrent/refractory solid tumors in children and young adults

    Published date:
    05/26/2022
    Excerpt:
    Children and young adults (CYA) with EGFR-expressing recurrent/refractory (R/R) ST were enrolled...EGFR806 directed CAR-T cells have an acceptable toxicity profile in CYA with R/RST and demonstrate anti-tumor activity in some patients.
    DOI:
    10.1200/JCO.2022.40.16_suppl.2541
    Trial ID:
    STRIvE-01